A $350 genetic test developed by researchers at Mayo Clinic in Rochester, Minn., and subsequently licensed to Phenomic Sciences, seeks to assign risk scores to patients regarding their likelihood of responding well to GLP-1 anti-obesity drugs like Wegovy or Ozempic.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
